Economic Atlas
Companies/Eupraxia Pharmaceuticals Inc.
Company profile

Eupraxia Pharmaceuticals Inc.

NASDAQ: EPRX · Healthcare · Biotechnology
Canadian filerHQ Victoria, BCCIK 0001581178Reports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
42D
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$38.6M
Employees
49
as of 2026-08-13
Market cap
$217.0M
as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$0$02025
Net income-$38.6M-$38.6M2025
Total assets$86.2M$86.2M2025
Liabilities$5.7M$5.7M2025
Equity$82.0M$82.0M2025

Revenue trend

FY2023 – FY2025 · USD
FY23
FY24
FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Eupraxia Pharmaceuticals Inc.’s revenue?

Eupraxia Pharmaceuticals Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare
CytoDyn Inc.30DCapricor Therapeutics, Inc.57CMinerva Neurosciences, Inc.37DCorbus Pharmaceuticals Holdings, Inc.46DImmuneering Corporation43DNkarta, Inc.47D
Key facts
CEOJames A. Helliwell
SectorHealthcare
IndustryBiotechnology
HeadquartersVictoria, BC
ExchangeNASDAQ: EPRX
Employees49
IPO date2024-04-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.